Abstract 2070P
Background
Healthy lifestyle habits such as avoiding overweight, engaging in moderate physical activity for at least 150 minutes per week, and getting good quality sleep have not only been shown to decrease the incidence of certain cancers, but also have a clear impact on the outcome of patients diagnosed with breast cancer. Adherence to these recommendations has an impact on quality of life, and some studies suggest their beneficial effect on patient survival.
Methods
We included 181 patients diagnosed with breast cancer in different stages, Multivariable ambulatory circadian monitoring of skin temperature, motor activity, light exposure, and sleep patterns was performed for 7 consecutive days through a small watch-like device called Kronowise 3.0. The patients are divided into 3 groups: group 1 includes metastatic patients, group 2 consists of patients with early-stage breast cancer undergoing chemotherapy, and group 3 comprises patients with early-stage breast cancer under follow-up (more than 1 year after the completion of chemotherapy).
Results
The table describes the mean age with standard deviation, physical activity categorized as patients who achieve ≥ 150 minutes of moderate physical activity (MPA) per week, ≥ 300 minutes of moderate physical activity per week, ≥ 75 minutes of vigorous physical activity per week, patients with good sleep hygiene (between 7 and 9 hours of sleep per day), patients with < 10 hours of sedentary behavior, and the percentage of patients with overweight and obesity in each group. Table: 2070P
Median Age | MPA ≥ 150 min | MPA ≥ 300 min | Vigorous activity ≥ 75 min | Sedentariness < 10 hours | Median night sleep (hours) | Median BMI | BMI 25-30 | BMI ≥ 30 | |
GROUP 1 | 57 ± 9 | 65% | 45% | 4% | 90% | 7.5 | 25.53 | 21% | 20% |
GROUP 2 | 50 ± 7 | 88% | 73% | 15% | 100% | 6.7 | 23.26 | 15% | 5% |
GROUP 3 | 55 ± 10 | 89% | 79% | 20% | 100% | 6.5 | 26 | 20% | 17% |
Conclusions
Despite breast cancer patients not being sedentary and having higher levels of moderate physical activity compared to the general population, the occurrence of vigorous physical activity is quite low among these patients. It is imperative to establish proper sleep hygiene in these patients in order to improve parameters and reduce the rates of overweight and obesity, particularly among the metastatic population and long-term survivors, where these rates are significantly higher.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This abstract is part of the CLARIFY project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 875160.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06